CLEVAIR
CLEVAIR-HTA provides AI execution software for health technology assessment (HTA) and joint clinical assessment (JCA) teams, connecting evidence strategy through dossier delivery.
CLEVAIR-HTA is built specifically to address EU HTA Regulation 2021/2282 and support the JCA process from evidence strategy to submission-ready dossier in one continuous workflow. The platform is designed for pharma teams working on market access, regulatory, medical writing, and evidence operations, connecting comparator logic, evidence strategy, drafting, and review in a single execution model.
Key People
- Marc Czarka - CEO - Owner